Introduction
Th e immune system prevents against infection involving infl ammatory processes resulting in a response to trauma or microbial infections and it is related to the process completion in order to extinguish the stimulus or to remove the tissue damage. Many diseases such as cardiovascular disorders, Alzheimer's disease, rheumatoid arthritis, cancer and infl ammatory bowel disease (IBD) are caused by infl ammatory processes and the course of the pathology continues because of the inappropriate or excessive responses that accompany them chronically [1, 2] .
Under homeostasis the gastrointestinal system represents a perfect balance between the host and the microbiota in a complex and dynamic process, with important role in the mucosal immunity. When this balance is lost the consequences can result in the increase in intestinal permeability and bacterial translocation across the intestinal mucosa, leading to a local and systemic immune activation implicated in many diff erent diseases including IBD. Th e two main forms of IBD include Crohn's disease (CD) and ulcerative colitis (UC) [3] [4] [5] [6] [7] .
When a patient develops IBD, he acquires the disability of recognition of pattern recognition receptors (PRRs) as Toll-like receptors (TLR), on epithelial and immune cells in the intestine. Th is leads to the incapacity of diff erentiating between pathogenic and commensal bacteria (macrophages and dendritic cells on recognition of commensal microbiota modify their status to an activated phenotype) and consequently, extends the activation of nuclear factor kappa B (NFκB), a pro-infl ammatory transcription factor which triggers overproduction of infl ammatory cytokines, such as tumor necrosis factor (TNF) -α and interleukins (IL) -1β, -6, -12 and -23 ( Fig. 1) . Processed antigens are presented to naïve CD4 T-cells and the natural killer T cells produce IL-13, strongly associated with the epithelial cell barrier disruption. Circulating T cells bind to colonic endothelial cells through the mucosal vascular adhesion molecule 1, whose production increases in the infl amed intestine. Th is is accompanied by upregulation of infl ammatory chemokines and consequent recruitment of circulating leukocytes that leads to the perpetuation of the infl ammation. Th e chronic infl ammatory process involves modifi cations on the bowel habits, pain, bleeding, and increases the risk for bowel cancer [8] [9] [10] [11] .
UC and CD may aff ect adults and young population driving to a prolonged course and recurrence, aff ecting education, capacity for work and quality of life. Th e care IBD patient should have is a challenge due to the heterogeneous nature of the disease and the lack of consensus in many areas of practice. IBD management is usually conducted by pharmacotherapy but patients should be approached in diff erent ways to have a follow up to match their needs and improve their quality of life. Th is should be done by a multidisciplinary team and the treatment should go beyond the use of conventional therapies.
Several substances as corticosteroids, thiopurines and biologic agents are available and antibiotics, probiotics, and nutritional supplements can be used as supportive therapy. Th us, the use of alternative therapies as omega-3 polyunsaturated fatty acids (PUFA) (n-3 or ω3 FA) could bring important benefi ts to the IBD patient [8, [12] [13] [14] [15] .
Methods
Th is review was based on a survey of articles in order to bring relevant information about the use of ω3FA. We used the following databases: PubMed, Medline, Scielo, Scopus and Lilacs. A retrospective search was carried out to identify relevant clinical trials or epidemiological studies and reviews limited to indexed scientifi c articles involving humans and animals.
Infl uence of diet on IBD patients
Th ere is a genetic predisposition to the development of IBD but its increasing incidence in developing countries suggests that environmental factors, such as diet, are also critical components of susceptibility to the occurrence of the disease. Authors have shown that highest consumption of red meat, saturated fat, refi ned carbohydrates, and food additives as well the low amount of dietetic fi bers, fruits, vegetables and antioxidants had increased risk of developing IBD. Dietary compounds as protein, linoleic acid (ω6FA) and digestible carbohydrates may contribute to the pathogenesis because they cause intestinal microbiota modifi cations leading to an increase in intestinal permeability, and infl ammation processes augment [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] .
Several authors have shown that, in addition to modifi cations in the food choices, the use of ω3FA may bring benefi ts because may infl uence the development or course of IBD [16, [26] [27] [28] [29] [30] . Normally, the recommended intake of ω3FA is 1.6 g/day for men and 1.1 g/day for women. Th is intake can come from the regular food consumption or from supplementation with fi sh or olive oil or use of emulsions consisting of coconut oil, soy, olive oil or fi sh. Literature shows converging opinions about a daily recommendation but authors agree that 500 mg/day of eicosapentaenoic acid/docosahexaenoic acid could bring health benefi ts. Di Nicolantonio et al [31] suggested 2 servings of fatty fi sh per week for the general population. Th ere is no consensus on ω3FA dietary recommendations for IBD patients. to be essential nutrients because the body does not have the capacity to produce them endogenously. Th ey can be found in signifi cant proportions in diff erent food sources, as in linseed, nuts and fi sh. Examples of these acids are α linoleic acid with a chain with 18 carbon atoms and 3 double bonds (C18:3n-3), eicosapentaenoic acid (C20:5n-3), and docosahexaenoic acid ( Fig. 2 ) (C22:6 n-3) [32] [33] . While saturated fatty acids are related to insulin resistance, higher levels of triglycerides, weight gain, increase in the adipocyte size and increase in adipose tissue infl ammation, ω3FA improve blood lipid levels, reduce weight and attenuate infl ammation processes implicated in cardiovascular diseases and other infl ammatory diseases. Th ey can also improve neural function and sensitivity to acetylcholine, balance the membrane fl uidity and decrease post-exercise infl ammation leading to adaptations to exercises such as decreasing aspects of fatigue and improving peripheral neuromuscular function [32, [34] [35] [36] .
Pathophysiological data
Th e interest in the use of ω3 FA has grown tremendously in the last years. Th ey are substrates for infl ammatory and anti-infl ammatory eicosanoid production, such as prostaglandins and leukotrienes, and so they have been used to the prevention of diff erent infl ammatory diseases in animals and humans (Fig. 3) . One possibility to explain the benefi cial eff ects of ω3FA is the competition that avoids conversion of arachidonic acid to pro-infl ammatory eicosanoids such as prostaglandins, leukotrienes and lipoxins through the cyclooxygenase or lipoxygenase enzymes. Eicosapentaenoic acid and docosahexaenoic acid can replace arachidonic acid and inhibit pro-infl ammatory mediator production. Th ey may also inhibit infl ammation acting in leukocyte chemotaxis, adhesion molecule expression and leukocyte-endothelial adhesive interactions, and suppressing the production of other infl ammatory cytokines, and T-helper 1 lymphocyte reactivity. Furthermore, ω3FA are substrates to the synthesis of resolvins, maresins and protectins, indispensable in resolving infl ammation processes [26, [37] [38] [39] [40] [41] .
Th e beginning of infl ammation is important for the body to make the defense against trauma or microorganism infection, and so is the fi nalization of the process. If this does not occur, the organism will develop a disease. In this duet, i.e. the beginning and the end of infl ammation process, the same lipid substances are involved. Th us, the use of eicosapentaenoic acid and docosahexaenoic acid may be promising in minimizing or preventing infl ammatory diseases such as IBD [42] [43] [44] . Both animal and clinical studies show that these acids may have a potential role in the treatment of IBD. Besides, patients see them as both safe and natural [30] . IBD patients may exhibit a defi ciency in essential fatty acids, and ω3FA supplements may benefi t IBD patients by inhibiting natural cytotoxicity (by changing arachidonic acid metabolites) and/or improving oxidative stress. Th e anti-infl ammatory actions of ω3FA may also be associated with their ability to change the composition of the cell membrane and the ability to activate the antiinfl ammatory transcription peroxisome proliferator activated receptor (PPAR) γ [26, 30, [45] [46] [47] [48] .
Th ere is evidence that the gastrointestinal mucosa is highly responsive to long-chain PUFA such as ω3. Th e intake of ω3FA can be helpful in the treatment of UC and CD as it can alleviate the symptoms and help the recovery of the mucosal due to its anti-infl ammatory properties. Reasons probably are related to the reduction in the intestinal production of the precursor of pro-infl ammatory cytokines (leukotrienes and prostaglandins) of odd series. Furthermore, there is evidence that these acids may reduce the protein expression of intestinal NFκB p65 related to apoptotic cells [28, 41, [48] [49] [50] [51] [52] .
ω3FA may infl uence the membrane-cytoskeletal structure and function in CD4 + T cells leading to the reduction in [33] and Din et al [37] Figure 3 Structure of omega 3 fatty acids: fi rst double bond at the third carbon molecule from the methyl end of the chain. Th ere are three possibilities for names: C18:3n-3, C20:5n-3 and C22:6n-3omega, respectively linolenic acid, eicosapentanoic acid and docosahexanoic acid the infl ammation processes [22] . TLR and nucleotidebinding oligomerization domain proteins (NOD) have a critical role in the detection of microbial infection and induction of infl ammatory and immune responses. When both TLR and NOD are activated, there is activation of NFκB which stimulates synthesis of pro-infl ammatory cytokines. Studies are associating TLR4 and NOD signaling in multi-layered IBD, interfering in pathogen-associated molecular patterns leading to acute and chronic intestinal infl ammation [10, 49, 53, 54] .
Results of clinical studies
Many authors have studied the role of omegas in the prevention, treatment and maintenance of remission of infl ammatory diseases such as IBD. Pearl et al [55] studied colonic mucosa biopsies from 69 UC patients and found that infl amed mucosa had higher levels of arachidonic, docosapentaenoic and docosahexaenoic acids and lower levels of linoleic, α-linolenic and eicosapentaenoic acids compared with the control group. Th e severity of infl ammation was positively associated with the levels of arachidonic, docosapentaenoic and docosahexaenoic acid and negatively associated with levels of linoleic, α-linolenic and eicosapentaenoic acids suggesting that there are modifi cations in fatty acid metabolism in the infl amed gut mucosa. Th ese modifi cations can off er novel targets for intervention and nutritional strategies should also be considered. Table 1 summarizes the studies showing the eff ects of ω3FA in diff erent types of participants; some show an important role of ω3FA in the course of CD, UC and reduction of colorectal cancer and polyp, while others provided inconclusive or negative results [56] [57] [58] [59] [60] [61] [62] .
Th e controversial fi ndings on the relationship between ω3FA and IBD (as seen in Table 1 ) may be due to a number of reasons: 1) diff erent forms of ω3FA have diff erent eff ects when compared to the native form found in fi sh; 2) genetic diff erences in ω3FA receptors may interfere with the responsiveness to fatty acid supplementation; 3) modifi cations in G-protein receptors and PPAR-α (considered to be a dietary lipid sensor); and 4) diff erences or problems in their methodology (insuffi cient number of patients, short period of study, heterogeneity of disease, lifestyle and other aspects of the studied population). Th ese aspects may interfere in the effi cacy of ω3FA in controlling symptoms, infl ammation and remission in IBD patients [8, 16, 30, 63, 64] .
ω3FA in animal models
Literature is also rich in studies using ω3FA in diff erent types of animal models. Table 2 presents some studies showing that these acids may reduce weight loss and intestinal permeability, improve the intestinal morphology and barrier function and decrease the synthesis of infl ammatory markers as TNF-α, IL-6, IL-1β, prostaglandin E2 and expression of TLR4 and NFκB [28, 49, [65] [66] [67] .
ω3FA and pain ω3FA are shown to regulate pain, depending on the amount of intake and subsequent cellular distribution. When a large amount of ω3FA was administered, reduced thermal hyperalgesia was observed compared with a group that received a large amount of linoleic acid, suggesting that there is a dose-dependent association between these acids and pain control. Pain relief was observed in several pathologies, including IBD, possibly because ω3FA reduce proinfl ammatory cytokine and eicosanoid production. Th e use of ω3FA can also block the activity of mitogen-activated protein kinase related to the modulation of central sensitization induced by infl ammatory and neuropathic pain. Linolenic acid declines the production of lysophosphatidic acid that is strongly related to the development of neuropathic pain [68] [69] [70] [71] [72] [73] . It has been hypothesized that the eff ects of docosahexaenoic acid in pain control are due to its anti-infl ammatory eff ect via suppression of the arachidonic acid cascade; inhibition of voltage-gated sodium channels; and promotion of the agonistic action toward transient receptor potential vanilloid 1 (related to infl ammation processes and calcium channels inhibition). Th ey also found that docosahexaenoic acid reduces pain indirectly through the release of an endogenous opioid peptide β-endorphin and not only because it acts on the opioid receptor [74, 75] . Other studies showed that increased consumption of ω3FA and decreased consumption of ω6FA can modify endocannabinoid production in humans thereby suggesting that their derivatives could have physical and/or psychological pain modulating properties [76, 77] . 
Concluding remarks
IBD is considered a public health problem owing to the high cost it incurs for the Public Health System and the burden it has on the patients' quality of life. Several studies show that ω3FA lead to the production of resolvins, protectins and maresins which attenuate the infl ammatory processes possibly benefi ting IBD patients. However, there are many controversies over the ω3FA eff ects on IBD, and results of the studies should be interpreted with caution due to the enormous variability in the size of the samples, the amount of ω3FA administered and the methodology employed. Studying the pharmacology of ω3FA will help establish their real eff ects, thus bringing new possibilities to the treatment of infl ammatory diseases. More research is warranted to fully elucidate how these acids infl uence IBD and to defi ne the daily amount recommended to help prevent or induce remission of IBD. Generoso et al [28] Intestinal injury caused by Escherichia coli in pigs Improvement in intestinal morphology and barrier function; reduction in TNF-α, prostaglandin E2 and expression of TLR4 and NFκB
Liu et al [49] Colitis in rats Reduction in the expression of adhesion molecules and vascular endothelial growth factor A receptor-2; down regulation of TNF-α and IL-1β
Ibrahin et al [65] ; Tyagi et al [66] Colitis in mice Signifi cant reduction in colonic pro-infl ammatory eicosanoids Bosco et al [67] TNF-α, tumor necrosis factor-α; TLR4, Toll-like receptor 4; NFκB, nuclear factor kappa B; IL-1β, interleukin-1β
